Mirikizumab Pharmacokinetics and Exposure‐Response in Patients With Moderately‐To‐Severely Active Crohn's Disease: Results From Two Randomized Studies
ABSTRACT Mirikizumab is a humanized anti–interleukin‐23‐p19 monoclonal antibody approved for both moderately‐to‐severely active ulcerative colitis and moderately‐to‐severely active Crohn's disease (CD). We characterized pharmacokinetics (PK) and exposure‐response (ER) of mirikizumab in relation...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|